Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Tim, Laranjeira, Angelo B.A., Collins, Taylor B., De Togni, Elisa S., Wong, Abigail J., Fulbright, Mary C., Ruzinova, Marianna, Celik, Hamza, Challen, Grant A., Fisher, Daniel A.C., Oh, Stephen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791597/
https://www.ncbi.nlm.nih.gov/pubmed/34644371
http://dx.doi.org/10.1182/bloodadvances.2020002804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791597/
https://www.ncbi.nlm.nih.gov/pubmed/34644371
http://dx.doi.org/10.1182/bloodadvances.2020002804

Ejemplares similares